The market size of the Global Rare Kidney Diseases Market is predicted to show an 16% CAGR during the forecast period. Kidney diseases have the potential to intensify over time, eventually leading to kidney failure, which is when the kidneys completely stop working. In addition, having one of these diseases can put you at a higher risk for developing another condition, such as cardiovascular disease. At least 150 distinct conditions are classified as rare kidney diseases, and the majority are inherited. The diagnosis and treatment of rare kidney diseases as a group may present overlapping difficulties, even though individual cases of these diseases present unique obstacles. Diagnosis, management, and treatment of inherited kidney disorders are complicated, especially when multisystem complications are present. These diseases can result in numerous physical and mental impairments, lowering life expectancy and reducing the quality of life. In the last two years, the COVID-19 infection severely affected the human lifestyle and approach towards chronic disease treatment. This led to delayed detection of rare kidney diseases and became responsible for the increase in the number of patients.
Several important factors are responsible for the growth of the rare kidney disease market. It is anticipated that the increasing use of next-generation sequencing techniques will improve diagnostic accuracy for rare kidney diseases, aid in elucidating the molecular mechanism of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility allow for more prolonged patient survival, but frequently at the expense of their quality of life. FDA approvals, Government initiatives and funding also contribute to expanding the market for such complicated diseases. In 2021, IgA nephropathy was rare kidney disease, and the FDA approved the first medication to reduce urine protein. The FDA had approved Tarpeyo (budesonide) delayed-release capsules to treat adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression by lowering proteinuria (increased protein levels in the urine).
Multiple factors, including unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not reflect underlying pathophysiological mechanisms, have impacted therapeutic advancements in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.
The Rare Kidney Diseases market is segmented into target indications, type of molecule, and route of administration. Target indication segment includes IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and others. Another segment is a type of molecule, which comprises Small Molecules and biologics. The subsegment biologics include Monoclonal Antibody, Hormone, Recombinant Protein, and Others. The last segment is the route of administration which has Oral, Intravenous, Subcutaneous, and other routes as subsegments.
According to regional analysis, North America will lead the global Rare Kidney Diseases market during the forecast period due to rapid clinical advancement breakthroughs and research for treatments of kidney diseases.
The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.